FDA Approves Outlook Therapeutics' LYTENAVA as First Ophthalmic Bevacizumab for Wet AMD After Three Prior CRLs

Three complete response letters. One successful appeal. One approval.

On July 24, 2026, the FDA approved ONS-5010/LYTENAVA™ (bevacizumab-vikg) — Outlook Therapeutics' ophthalmic bevacizumab formulation — for the treatment of neovascular age-related macular degeneration (wet AMD), according to the company's July 24, 2026 news release on GlobeNewswire.

LYTENAVA™ is now the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States, per that release.

The regulatory path ran through three CRLs before Outlook filed an appeal. In May 2026, the FDA granted that appeal, concluding that substantial evidence of effectiveness had been established for LYTENAVA™ despite the third CRL to the contrary, per Pearce IP's July 24, 2026 legal analysis. The FDA accepted Outlook's resubmitted Biologics License Application in June 2026 and assigned a PDUFA target date of July 29, 2026. The approval came July 24, 2026 — five days ahead of that date — per the company's July 24, 2026 GlobeNewswire release.

Outlook describes the product as positioned across what it calls the approximately $8.5 billion U.S. Retina Market, per the company's SEC filing (Exhibit 99-1, filed July 24, 2026). The company also anticipates 12 years of Reference Product Exclusivity under the BPCIA, per the same filing.

"FDA approval of LYTENAVA marks a defining moment for Outlook Therapeutics and creates a significant opportunity for the Company in the United States," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics, in the company's August 14, 2026 Q3 fiscal year 2026 financial results release on GlobeNewswire.

The product already holds international approvals: LYTENAVA™ was approved in the EU in May 2024 and in the UK in July 2024, with commercial launches in the UK and Germany in June 2025, per the Pearce IP July 24, 2026 analysis. Outlook expects to make LYTENAVA™ available to eligible U.S. patients before year-end, per the July 24, 2026 GlobeNewswire release.

To fund the U.S. launch, Outlook priced a $55.0 million public offering of common stock and warrants on August 13, 2026, per the company's August 13, 2026 GlobeNewswire announcement. Each unit — one share plus one warrant — was priced at $0.99. The warrants carry an exercise price of $1.10 per share and became exercisable immediately. The offering was expected to close August 14, 2026, subject to customary conditions.

The 12-year exclusivity clock is now running. Forward revenue targets for the U.S. market were not located in the press releases or SEC filings reviewed for this article and are therefore not reported here.